WO2005018634A1 - Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires - Google Patents
Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires Download PDFInfo
- Publication number
- WO2005018634A1 WO2005018634A1 PCT/CN2004/000970 CN2004000970W WO2005018634A1 WO 2005018634 A1 WO2005018634 A1 WO 2005018634A1 CN 2004000970 W CN2004000970 W CN 2004000970W WO 2005018634 A1 WO2005018634 A1 WO 2005018634A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monomethyl ether
- hematoporphyrin monomethyl
- use according
- treatment
- hematoporphyrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Definitions
- the present invention relates to the field of medicine, and more particularly to the use of hematoporphyrin monomethyl ether to treat ophthalmic diseases by applying photodynamic therapy (PDT) to the eye.
- PDT photodynamic therapy
- Vision loss is a common problem associated with aging and various eye diseases. Aging and other causes often cause the formation of harmful new blood vessels on the cornea, iris, retina, or choroid, causing vision loss and even vision loss. In many known eye diseases, including macular degeneration, ocular cytoplasmosis syndrome, myopia, and inflammatory diseases, choroidal neovascularization leads to bleeding and fibrosis, with eventual loss of vision.
- Age-related macular degeneration is the leading cause of vision loss in the elderly, with 10% of AMD patients accompanied by choroidal neovascularization, leading to rapid vision loss. According to statistics, 80% of the new blindness caused by AMD is caused by choroidal neovascularization.
- the choroidal neovascularization caused by AMD is mainly treated by laser photocoagulation (solid) method, which can close new blood vessels and delay vision loss.
- laser photocoagulation also destroys the normal choroidal tissue around the new blood vessels and the inner retinal tissue, causing vision loss. Patients often have atrophic scars and blind spots.
- Another problem with laser photocoagulation is that most patients are not suitable for laser photocoagulation because of the diffused blood vessels and unclear borders, or the curative effect is poor, and the recurrence rate is high.
- Photodynamic therapy is to administer a photoactive compound to a patient.
- the photosensitizer is concentrated at the site of the neovascularization, and then irradiated with a low-intensity laser to stimulate the photosensitizer to cause a photochemical reaction to selectively block the neovascularization.
- This method has stronger selectivity, lower laser intensity and less damage to surrounding normal tissues, and is expected to be an effective method for treating AMD.
- Photosensitizers used in photodynamic therapy include hematoporphyrin derivatives (HPD), benzoporphyrin derivatives (BPD), chlorin e6 monoaspartic acid amide (Npe6), and aluminum sulfonate (CASPc) ), Intermediary tetra (m-hydroxyphenyl) -hydrochlorin (mTIIPC), tin ethyl proorthocyanin (SnEt2), 5-aminolevulinic acid (ALA), etc., for photodynamic therapy of tumors and skin diseases .
- HPD hematoporphyrin derivatives
- BPD benzoporphyrin derivatives
- Npe6 chlorin e6 monoaspartic acid amide
- CASPc aluminum sulfonate
- mTIIPC Intermediary tetra (m-hydroxyphenyl) -hydrochlorin
- SnEt2 tin ethyl proorthocyanin
- U.S. Patent No. 5,798,349 and corresponding Chinese Patent No. 97192957 disclose the use of green porphyrins in photodynamic therapy of AMD and other choroidal neovascularization, but their therapeutic effects are still unsatisfactory.
- Green porphyrins are generally required to be combined with lipophilic carriers due to their low water solubility.
- the phototoxicity of the system is increased due to the prolonged clearance time in the body; on the other hand, in combination with the liposome carrier, the drug cannot be injected quickly, and it cannot be quickly switched between administration and treatment.
- the object of the present invention is to provide a new therapeutic agent and method, which can effectively treat various ophthalmic diseases caused by harmful blood vessel formation.
- a first aspect of the present invention there is provided the use of hematoporphyrin monomethyl ether, which is used for preparing a medicine for treating ophthalmic diseases.
- the ophthalmic disease is a disease caused by harmful neovascularization.
- the neovascularization occurs in the cornea, iris, retina or choroid. More preferably, said neovascularization occurs on the choroid.
- the ophthalmic disease is selected from the group consisting of macular degeneration, ocular cytoplasmosis syndrome, myopia, or an inflammatory disease.
- the hematoporphyrin monomethyl ether is a compound of the following structural formula
- R1 is 1-hydroxy-ethyl and 1-methoxy-ethyl
- R2 is 1-hydroxy-ethyl and 1-methoxy-ethyl
- the dose of the drug is 0.1-100 mg / kg body weight, calculated as hematoporphyrin monomethyl ether.
- the treatment is photodynamic therapy.
- the photodynamic treatment condition is that the irradiated light flux is 50-200 Joules / cm 2 , the illuminance is 50-800 mW / cm 2 , and the wavelength is 630 ⁇ 20 nm.
- hematoporphyrin monomethyl ether which is used as a photosensitizer for photodynamic therapy of ophthalmic diseases.
- a method for treating harmful neovascular diseases in the eye including the following steps: Giving a therapeutically effective dose of hematoporphyrin monomethyl ether to a patient in need of treatment, so that hematoporphyrin monomethyl ether accumulates in the neovascular area of the eye
- This area is irradiated with a laser of 630 ⁇ 20 nm for a sufficient time to allow the laser to be absorbed by hematoporphyrin monomethyl ether and block the neovascularization.
- Beneficial effects of the present invention As a better water-soluble drug, hematoporphyrin monomethyl ether is more convenient in drug administration, meanwhile, the elimination time in the body is short, the system phototoxicity is small, and rapid elimination can also make large blood vessels clear faster. Conducive to selective treatment of new blood vessels. Compared with other porphyrin derivatives, hematoporphyrin monomethyl ether has better selectivity and lower side effects, while having significant drug effect. BRIEF DESCRIPTION OF THE DRAWINGS
- Figure 1 shows the structural formula of hematoporphyrin monomethyl ether.
- Figures 2A and 2B show the effects of hematoporphyrin monomethyl ether on the chick embryo allantoic chorionic membrane (CAM) model.
- Figure 3 shows the primary and secondary blood vessel counts in the chicken embryo allantoic chorionic (CAM) model experimental group and control group.
- Figure 4 shows fluoroscopy of a choroidal neovascularization (CNV) model.
- Figure 5 shows choroidal neovascularization (CNV) model tissue sections.
- Figures 6A and 6B show the effect of hematoporphyrin monomethyl ether on a choroidal neovascularization (CNV) model.
- Fig. 6A is a control tissue section, and the arrow indicates choroidal neovascularization.
- Figure 6B is a tissue section of the experimental group. The arrow indicates the choroidal neovascularization, and a thrombus has formed inside the blood vessel.
- Figures 7A-E show hematoporphyrin derivatives (HpD), 5-aminoketovaleric acid (ALA), hematoporphyrin diethyl ether, hematoporphyrin monopropyl ether, and hematoporphyrin monomethyl ether on the CAM model, respectively. Damage to normal blood vessels.
- the inventors After intensive and extensive research, the inventors have screened a large number of compounds, and unexpectedly found that the compound hematoporphyrin monomethyl ether is particularly suitable for treating ophthalmic diseases.
- the optimal absorption wavelength of hematoporphyrin monomethyl ether is 630nm, the elimination time is short, and the photosensitivity can be eliminated within 24 hours, so it is suitable as a photosensitizer for photodynamic therapy for ophthalmic diseases.
- the present invention has been completed on this basis. Photoactive compounds
- a compound suitable for the present invention is hematoporphyrin monomethyl ether.
- Xu Deyu, Chen Wenhui, etc. disclosed the physicochemical properties, preparation methods of hematoporphyrin monomethyl ether in Chinese Journal of Laser Medicine (1993, 2: 3-7) and Chinese Patent Application No. 01131939, and their preparation methods in the treatment of tumors.
- Application; Chen Wenhui, Xu Deyu and others published the distribution of hematoporphyrin monomethyl ether in tumor-bearing mice in Journal of the Second Military Medical University (1990, 11: 118-122): Gu Ying, Liu Guangfan, etc.
- the photoactive compound suitable for the present invention has the following structural formula:
- R1 is 1-hydroxy-ethyl and 1-methoxy-ethyl
- R2 is 1-hydroxy-ethyl and 1-methoxy-ethyl.
- R1 is 1-hydroxy-ethyl
- R2 is 1-methoxy-ethyl
- R1 is 1-methoxy-ethyl
- R2 is 1-hydroxy-ethyl.
- Hematoporphyrin monomethyl ether has light absorption in the range of 395-635nm.
- Hematoporphyrin monomethyl ether can also be used in combination with other photoactive compounds; however, the effectiveness of treatment depends on the light being absorbed by the photoactive compounds. Therefore, if a mixture is used, the compounds with similar maximum absorption peaks are used in combination as good. Treatment mechanism
- the present invention relates to the treatment of ophthalmic diseases with photodynamics.
- Photodynamic treatment protocols lead to the reduction of harmful new blood vessel formation (especially choroidal new blood vessel formation), thereby treating related ophthalmic diseases and improving patient vision.
- a patient in need of treatment is administered a suitable photoactive compound in an amount sufficient to achieve an effective concentration of the photoactive compound in the patient's eye.
- the effective concentration of the compound is gathered in a desired area in the eye, and then the area is illuminated with light absorbed by the photoactive compound.
- Photodynamic therapy using hematoporphyrin monomethyl ether as a photosensitizer can be excited by light with a wavelength of 395-635 nm according to its absorption characteristics.
- Photoactive compounds are excited by light to generate reactive oxygen species and free radicals, causing photochemical damage to cells in the diseased area, blocking new blood vessels in the diseased area, thereby treating various ophthalmic diseases caused by harmful blood vessel formation, and ultimately improving the patient's vision.
- Dosing and dosage The photoactive compound can be administered by various routes, such as oral, parenteral, or rectal, or the compound can be placed directly into the eye. Parenteral administration is appropriate, such as intravenous, intramuscular or subcutaneous injection. Intravenous injection is the best.
- the dose of the photoactive compound can vary widely depending on the mode of administration, the type of formulation, and whether or not it is coupled to a targeting ligand. It is generally believed that there is a correlation between the formulation of the photoactive agent, the mode of administration, and the dosage level. In general, the typical dose range of hematoporphyrin monomethyl ether is from 0.1 to 100 mg / kg, the preferred dose range is from 0.5 to 50 mg / kg, and the more preferred dose range is from 1 to 10 mg / kg. Those skilled in the art can also experimentally determine the appropriate dose.
- the dose can be adjusted relative to other parameters, such as the luminous flux, light intensity, duration and dose used in photodynamic therapy, the time interval between administration and light irradiation, and the like.
- the use of these parameters should be adjusted to significantly improve vision without significant damage to normal eye tissue. Those skilled in the art can determine appropriate parameters through experiments.
- the luminous flux is also called light dose and light energy density; the illuminance is also called power intensity and power density. These terms are used and understood by those skilled in the art and are described herein.
- the target tissue of the eye is irradiated at the selected drug absorption wavelength.
- the selected wavelength range is generally around 630 ⁇ 20nm, and more preferably around 630 ⁇ 10nm. This range of wavelength has better penetration in the body tissue.
- the photoactive compound As a result of irradiation, the photoactive compound is in an excited state and interacts with other compounds to form singlet oxygen (Singlet Oxygen) and other free radicals, causing structural destruction of vascular epithelial cells.
- Singlet oxygen and other free radicals primarily damage cell membrane structures, including cell membranes, mitochondrial membranes, lysosomal membranes, and nuclear membranes.
- Vascular epithelial cell damage causes subsequent platelet aggregation, degranulation, and thrombosis, resulting in blockages and closure of blood vessels.
- the amount of light flux irradiated can vary widely. However, it is preferably 50-200 Joules / cm 2 .
- Change in light intensity is generally 50- 800raW / cm 2, at about 100- 600 mW / cm 2 being preferred. However, choosing to use a higher light intensity can shorten the treatment time to achieve the same effect.
- the optimal time interval between photoactive compound administration and phototherapy also depends on the mode of administration and the form of administration Depending on the type of preparation.
- the time interval after photosensitizer administration is from 1 minute to 2 hours, preferably 5 to 30 minutes, and more preferably 10 to 25 minutes.
- the present invention provides a method for photodynamic treatment of ophthalmic diseases, comprising administering to a patient in need of such treatment a photoactive compound preparation sufficient to enrich a sufficient amount of photosensitizer in the eyes of the treated patient; allowing sufficient time for an effective amount of light
- the active compound is enriched in the patient's eye; the eye is illuminated with light suitable for absorption by a photosensitizer.
- hematoporphyrin monomethyl ether is used to effectively reduce or eliminate harmful new blood vessel formation in the cornea, iris, retina, or choroid by photodynamic therapy
- the method of the present invention can be used to treat harmful blood vessels. Formation and various eye diseases. Representative ophthalmic diseases include (but are not limited to): macular degeneration (age-related macular degeneration and other macular degenerations), ocular cytoplasmosis, myopia, and inflammatory diseases. Model used
- Mouse CNV model Used to evaluate the in vivo effect of photodynamic therapy on choroidal neovascularization.
- Rat CNV model Used to evaluate the in vivo effect of photodynamic therapy on choroidal neovascularization.
- Rabbit corneal neovascularization model used to evaluate the in vivo effect of photodynamic therapy on corneal neovascularization. Evaluation of treatment
- the effect of photodynamic therapy on animal CNV models can be used to observe the damage of endothelial cells and choroidal neovascularization in histological sections.
- the destruction of new blood vessels is manifested by vacuoles in the cytoplasm of vascular endothelial cells, abnormal shrinkage of the nucleus, platelet aggregation and the formation of blood clots in the vascular cavity.
- Another method is to observe the reduction of new blood vessels with angiography at a specific time after treatment.
- CAM model use the following method: 37 ° C incubator, air chamber upwards, rotate 3 to 4 times a day, until the 9th day of incubation, disinfect the surface of the breeding eggs and punch 1 or 2 holes at the top of the air chamber.
- a rectangular area 1.0 cm XL 5 cm from the egg shell projection site 1 cm from the fetal head and between the two anterior yolk veins was cut through the egg shell, and a small hole with a diameter of about lram was slightly cut through the egg shell membrane.
- a small amount of sterile purified water was added dropwise to separate the egg shell membrane at the edge of the pores, and a sterile microporous filter carrier with a diameter of 6 mm was placed on the CAM with the least blood vessels.
- Example 2 10 ⁇ l of hematoporphyrin monomethyl ether prepared in Example 1 was added to the center of the carrier, and 10 ⁇ l of physiological saline was added to the control group.
- the light was irradiated with gold vapor laser 15 minutes after dosing, the spot diameter was 2000 ⁇ m, the power density was 100 mW7cm 2 , the light irradiation time was 200 s, and the energy density was 20 J / cm 2 .
- seal the window with sterile clear glue mark and then incubate for 3 days in an incubator at 37.8 ° C. After 3 days of light treatment, each egg 5ml ⁇ Inject 1: 1 methanol, acetone and other equal amount of fixed solution 2.
- the blood vessels were counted at the same magnification, with the edge of the experimental site (that is, the edge of the microporous filter carrier) as the primary blood vessel within 1 mm, and the edge of the experimental site with 5 mm as the secondary blood vessel. That is, it is sent with the carrier as the center, and the angle between the radius of the filter and the radius of the filter is less than 45 degrees.
- the blood vessels passing through and bypassing are not counted.
- the primary and secondary blood vessels were observed and counted separately.
- the number of primary and secondary vessels in the control group was 34.7 and 45.2 respectively, and the experimental group was 21 and 32.5, respectively.
- the experimental group was significantly less than the control group.
- Example 3 Damage effects of different photosensitizers on normal blood vessels
- Hematoporphyrin derivative (purchased from Beijing Institute of Pharmaceutical Industry) was dissolved in a 5% glucose solution to a final concentration of 20 mg / mL.
- 5-aminoketovaleric acid (ALA) (purchased from Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.), 50mg / mL, soluble in water, adjusted to P ⁇ 6, newly prepared before the test, in vivo photodynamic response, 1% ALA drug
- the dose can be converted into the photosensitizing substance protoporphyrin (see literature BWHenderson, et fl / Photosensization of murine tumor, vasculature, and skin by using 5-aminol e vulinic acid-induced porphyrin,
- Hematoporphyrin diethyl ether, hematoporphyrin monopropyl ether, and hematoporphyrin monomethyl ether purchased from Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.
- the above drugs are lyophilized preparations, dissolved in 0.9% physiological saline before use, and prepared separately A 20 mg / mL solution was set aside.
- the eggs are sterilized and transferred to a constant temperature incubator.
- the eggs are incubated at a temperature of 37 ° C and a humidity of 60% until the third day.
- a 3mm diameter hole is punched in the top of the air chamber, and 30uL of photosensitizer is locally injected into the CAM (about 30mm 2 ).
- the CAM area was washed twice with 150 uL of phosphate buffered saline (PBS), and laser irradiation was performed.
- PBS phosphate buffered saline
- the 630nm semiconductor laser is grouped according to different drugs, agents, and different photodynamic parameters. At the same time, no-light administration, no-light administration, and a blank control group are set.
- Example 4 Establishment of a CNV mouse model.
- the CNV model was established as follows: Twenty adult male C57BL-6J mice were randomly selected, each weighing 25g to 26g. Mice were anesthetized with intraperitoneal injection of 0.3% sodium pentobarbital 200 L, 2% tropinamide and 10% neoflume mydriatic. A laser (wavelength 810 nm, diameter 75 ⁇ m, irradiation time 0.1 s, power 140 mW) was introduced into the eyes of the mouse through a slit lamp and a contact lens. Fundus fluorescein angiography 1 week after laser irradiation (fundus fluorescence angiography, FFA). Nine animals were selected with no fluorescence leakage at the photocoagulation point and milky white point at the photocoagulation point (as shown in Fig. 4).
- the eyeballs were removed and fixed in 2% glutaraldehyde and 4% polyformic acid, respectively.
- the eyeballs were dissected, the laser spot was identified through a dissecting microscope, and the tissue pieces were cut. It was fixed with 1% osmium tetroxide, dehydrated with ethanol gradient, replaced with ethylene oxide, embedded with epoxy resin, serially sectioned, stained with toluidine blue, and observed under a light microscope. .
- Example 3 Four CNV model mice prepared according to Example 3 were injected with a lyophilized preparation of bloodline methyl ether at a dose of 10 mg / kg in the tail vein.
- the light was irradiated with a gold vapor laser 15 minutes after the injection, the spot diameter was 2000 ⁇ m, the power density was 100 mW / cm 2 , the light irradiation time was 200 s, and the energy density was 20 J / cm 2 .
- Another 4 CNV model mice prepared in Example 3 were injected with the same amount of physiological saline in the tail vein as a control. Result judgment
- mice were sacrificed with an excessive amount of sodium pentobarbital, and the eyeballs were removed and fixed in 2% glutaraldehyde and 4% paraformaldehyde, respectively.
- the eyeballs were dissected, and the laser spots were identified through a dissecting microscope. It was fixed with 1% osmium tetroxide, dehydrated with ethanol gradient, replaced with ethylene oxide, embedded with epoxy resin, serially sectioned, stained with toluidine blue, and observed under a light microscope.
- the experimental group showed choroidal capillary thrombosis, retinal pigment epithelium arrangement lost normal continuity, disordered outer segment arrangement, vacuolation, outer granule layer cells condensed, and the inner retinal layer was normal (Figure 6B).
- BN Male brown Norwegian (BN) rats weighing 180-220 g, both anterior segment and fundus examination were normal before the experiment.
- the rats were anesthetized by intraperitoneal injection of 10% chloral hydrate, and the pupils were dilated with compound tropicamide eye drops, and the cornea was placed With a contact lens, a chirped laser with a wavelength of 647 nm was used to photocondense 8 points around the optic nipple.
- the laser power is 360mW
- the exposure time is 0.05s
- the spot diameter is 50um.
- FFA fluorescein fundus angiography
- ICGA indocyanine green angiography
- Histopathological examination is as follows: The model rats are sacrificed, the eyeballs are removed, and 2.5% glutaraldehyde is fixed. The eye tissues of the photocoagulation site are cut out, and after ethanol dehydration, transparent, wax-impregnated, and paraffin-embedded, serial sections, HE staining and sealing And observed under a light microscope. Transmission electron microscope specimens were observed after post-fixation, dehydration, infiltration and embedding, and section staining. Pathological examination showed that in the photocoagulation zone 8 ⁇ 1 (: 11 ' 8 membrane rupture, retinal pigment epithelium (RPE) cells proliferated to the inner retinal layer. There was a large number of neovascularization in the choroid. Hematoporphyrin monomethyl ether on rats CNV photodynamic therapy effect
- CNV model rats were injected with 5 mg / kg, 10 mg / kg, and 20 mg / kg of hematoporphyrin monomethyl ether in the tail vein, and the semiconductor laser therapeutic apparatus with a wavelength of 630imi was used to irradiate CNV.
- the control group was set up without medicine, without medicine and without light.
- FFA and ICGA examinations were performed before and 7 days after PDT. The animals were sacrificed after 7 days of PDT treatment, and the eyeballs were removed for histopathological examination.
- the treatment results are divided into three levels: 0 level, no vascular closure; 1 level, only CNV closed; 2 level, retinal and choroidal blood vessels are closed.
- 0 level no vascular closure
- 1 level only CNV closed
- 2 level retinal and choroidal blood vessels are closed.
- grade 0 showed that there was still leakage of fluorescence in the photocoagulation spot
- grade 1 showed that the leakage of fluorescence in the photocoagulation spot disappeared and retinal vascular filling
- grade 2 showed lack of retinal vascular filling and dye accumulation in the retina.
- Level 1 selective closure of CNV and choroidal vessels
- Level 2 Closed choroid and retinal blood vessels. It can be seen from Table 2 that when the dosage is 10 mg / kg, the interval between irradiation and administration is 15 minutes, and the energy density is 150 J7 cm 2 (power density 600 mW / cm 2 , irradiation time is 250 seconds). Ether photodynamic therapy has the best effect on CNV in rats. All 9 CNVs have been selectively closed, but they have no effect on the choroidal and retinal vessels around the CNV.
- hematoporphyrin monomethyl ether can selectively destroy choroidal neovascularization, thereby treating ocular diseases such as age-related macular degeneration caused thereby.
- Example 7 Hematoporphyrin monomethyl ether photodynamic treatment of corneal neovascularization in rabbits
- New Zealand white rabbits weighing 2 ⁇ 3.5Kg were selected, the conjunctival sac was washed, and decaine (12.5mg / ml) was operated on.
- the eye was opened 3 times anteriorly, the eyelid was opened, and the upper cornea was sutured with a triangular needle.
- the end of the suture was about 2.5 mm from the limbus.
- the length of the suture embedded in the corneal stroma was about 3 mm.
- the new blood vessel growth was observed under the slit lamp observation. By the 18th day, the new blood vessel growth was strong.
- a model rabbit that successfully induced corneal neovascularization was injected with hematoporphyrin monomethyl ether 10 mg / kg on the ear margin vein on the 19th day after suture surgery.
- the corneal neovascularization was irradiated with a 514 nm argon laser at 20 minutes after injection.
- the laser power density was 650 mW / cm 2
- the energy densities were 50 J / cm 2 , 75 J / cm 2 , and 150 J / cm 2 , respectively.
- the control group was administered only without light, only the light without light, and the model control group. Effect observation
- the cornea was photographed by a slit lamp, a digital image scan of the computer, and the area of corneal neovascularization before and after PDT were calculated using a NIH Image image processing program.
- the results showed that at a laser energy density of 50 J / cm 2 and 75 J / cm 2 , corneal neovascularization in 30% and 48% of the model rabbits subsided, but neovascularization recurred after 3 to 4 days. With an optical density of 150 J / cm 2 , neovascularization in 68% of the model rabbits subsided without recurrence within 2 weeks. There was no change in the area of corneal neovascularization in the rabbits of the model control group, with and without light, and with and without light.
- results of this example show that hematoporphyrin monomethyl ether can selectively destroy corneal neovascularization, thereby treating the eye diseases caused thereby.
- results of the present invention show that hematoporphyrin monomethyl ether can effectively inhibit harmful blood vessels such as choroidal neovascularization, and thus can effectively treat various ophthalmic diseases caused by harmful blood vessel formation, such as the harmful effects on the cornea, iris, retina or choroid. Ocular diseases caused by neovascularization, especially age-related macular degeneration.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031505538A CN100534428C (zh) | 2003-08-25 | 2003-08-25 | 血卟啉单甲醚在治疗眼科疾病中的应用 |
CN03150553.8 | 2003-08-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005018634A1 true WO2005018634A1 (fr) | 2005-03-03 |
Family
ID=34201010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2004/000970 WO2005018634A1 (fr) | 2003-08-25 | 2004-08-20 | Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN100534428C (zh) |
WO (1) | WO2005018634A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105435225A (zh) * | 2015-12-27 | 2016-03-30 | 海宁市绿升医药科技有限公司 | 注射用二氢卟吩e6单酯冻干制剂及其制备方法 |
CN109091685A (zh) * | 2018-08-10 | 2018-12-28 | 北京市眼科研究所 | 一种对角膜炎提取细菌病原体的灭活方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1213314A (zh) * | 1996-03-11 | 1999-04-07 | Qlt光治疗股份有限公司 | 通过对眼的光动力学治疗改善视力 |
CN1412189A (zh) * | 2001-10-17 | 2003-04-23 | 上海复旦张江生物医药股份有限公司 | 3-(或8)-(1-甲氧基乙基)-8-(或3)-(1-羟乙基)-次卟啉ix的合成方法 |
-
2003
- 2003-08-25 CN CNB031505538A patent/CN100534428C/zh not_active Expired - Lifetime
-
2004
- 2004-08-20 WO PCT/CN2004/000970 patent/WO2005018634A1/zh active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1213314A (zh) * | 1996-03-11 | 1999-04-07 | Qlt光治疗股份有限公司 | 通过对眼的光动力学治疗改善视力 |
CN1412189A (zh) * | 2001-10-17 | 2003-04-23 | 上海复旦张江生物医药股份有限公司 | 3-(或8)-(1-甲氧基乙基)-8-(或3)-(1-羟乙基)-次卟啉ix的合成方法 |
Non-Patent Citations (3)
Title |
---|
HE SHOUZHI ET AL.: "The new development of photodynamic therapy for aging-macular degeneration", CHINESE JOURNAL OF OPHTHALMOLOGY, vol. 37, no. 2, March 2001 (2001-03-01), pages 158 - 160 * |
ZHANG Q.W. ET AL.: "Photodynamic therapy for CNV", OPHTHALMOLOGICAL SECTION OF FOREIGN MEDICAL SCIENCES, vol. 26, no. 3, 2002, pages 179 - 183 * |
ZHAO S. ET AL.: "The study of photodynamic therapy for eye diseases", CHINESE JOURNAL OF LASER MEDICINE & SURGERY, vol. 11, no. 1, February 2002 (2002-02-01), pages 51 - 53 * |
Also Published As
Publication number | Publication date |
---|---|
CN1589791A (zh) | 2005-03-09 |
CN100534428C (zh) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1353692B1 (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
TWI260327B (en) | Pharmaceutical compositions for treating ocular neovascular diseases | |
AU737204B2 (en) | Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts | |
Schmidt-Erfurth et al. | Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration | |
AU2002230567A1 (en) | Compositions for treatment of ocular neovascularization and neural injury | |
Wilson et al. | Photodynamic retinal vascular thrombosis. Rate and duration of vascular occlusion. | |
US20030093065A1 (en) | Method to treat age-related macular degeneration | |
US20050234531A1 (en) | Method to treat age-related macular degeneration | |
Kim et al. | Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness | |
CN1882339A (zh) | 黄斑变性和其他眼科疾病的缓解 | |
ES2224355T3 (es) | Composiciones y articulos para reducir los efectos de la inflamacion. | |
WO2005018634A1 (fr) | Ether de monomethyle d'hematoporphyrine utilise pour le traitement de troubles oculaires | |
Iliaki et al. | Photothrombosis of retinal and choroidal vessels in rabbit eyes using chloroaluminum sulfonated phthalocyanine and a diode laser | |
RU2408335C1 (ru) | Способ лечения возрастной макулярной дегенерации сетчатки | |
Husain et al. | Photodynamic therapy of exudative age-related macular degeneration | |
Favilla et al. | Phototherapy of posterior uveal melanomas. | |
Davidorf et al. | Treatment of iris melanoma with photodynamic therapy | |
RU2290973C1 (ru) | Способ лечения субретинальной неоваскулярной мембраны | |
AU2006201701B2 (en) | Methods and compositions for treatment of ocular neovascularization and neural injury | |
WO2000076454A2 (fr) | Compositions therapeutiques a usage ophtalmique et compositions therapeutiques destinees au traitement des lesions cerebrales centrales | |
Schuitmaker et al. | Evaluation of photodynamically induced damage to healthy eye tissues of rabbits using the second-generation photosensitizers bacteriochlorin a and mTHPC | |
Masuda | Treatment of Age-related Macular Degeneration | |
MXPA99005399A (en) | Use of green porphyrins for the manufacture of a medicament for the treatment of secondary cataracts | |
CZ204799A3 (cs) | Použití zelených porfyrinů pro výrobu léčiva k ošetřování sekundárního šedého zákalu | |
AU2002363336A1 (en) | Methods for treating ocular neovascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |